Journal of Immunotherapy and Precision Oncology shared a post on LinkedIn:
“We are excited to share that JIPO 2024 Impact Factor is 3.2.
This is the first impact factor reported for the Journal.
This major milestone and achievement would not have happened without the dedication and high professional performance of the Editorial team led by Dr. Aung Naing and to the high quality contributions of the authors and reviewers.
We thank all those who contributed to this achievement and looking forward to continuing support of all involved.”
More posts featuring Journal of Immunotherapy and Precision Oncology.